Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 5HIV Infections 4Acquired Immunodeficiency Syndrome 4Sarcoma, Kaposi 3Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tumor Virus Infections 1Triple Negative Breast Neoplasms 1Solid Cancers 1Sarcoma 1Papillomavirus Infections 1Neoplasm Metastasis 1Breast Neoplasms 1Breast Carcinoma In Situ 1Anus Neoplasms 1Advanced Neoplasm 1Adult Solid Neoplasm 1AIDS-Related Complex 1

Interventions

Gemcitabine 4pembrolizumab 3Docetaxel 3aflibercept 2Trastuzumab 2Specimen Handling 2Cisplatin 2Carboplatin 2vinflunine 1tipifarnib 1erdafitinib 1enzalutamide 1entinostat 1enfortumab vedotin 1cabozantinib 1avelumab 1Thalidomide 1Sorafenib 1Ramucirumab 1Radiotherapy 1Platinum 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Ipilimumab 1Introns 1Interleukin-12 Subunit p35 1Interleukin-12 1Interferon-alpha 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Urethral Neoplasms × Interferon alpha-2 × Clear all
NCT00082719 2015-05-14

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡